

17 June 2026

## **Clarification – Binding JV for Collie Collagen Facility**

Holista Colltech Limited (ASX: HCT) (Holista or the Company) refers to its announcement dated 5 May 2026 titled “Holista Executes Binding JV for Collie Collagen Facility” (“the Original Announcement”), in respect of the binding Joint Venture Agreement entered into with Swang Chai Chuan Limited (“HKEX: 2321, “SCC”) for the funding, development, and operation of an ovine nano-collagen production facility in Collie, Western Australia (“the Joint Venture”, or “JV”). The Company provides the following clarifying information.

Dr Rajen Manicka (“Dr Rajen”), a substantial shareholder of the Company, was not involved in the joint venture negotiations and is not a member of the board of the joint venture. He is the inventor of the pending patent over the collagen technologies that the Joint Venture is exclusively licensed to utilise.

In relation to the patents referred to in the Original Announcement, Holista previously held a patent titled “Collagen and Method for Producing Same”, which expired in May 2023. Building on that foundational technology, Holista Biotech Sdn Bhd developed further innovations, and a new and distinct patent application titled “Method for Producing Collagen from Animal Skin” was filed through Adastra, with Dr Rajen as the primary inventor. The new application advances the prior art of the expired patent through new data and updated methodologies, including improved bioburden outcomes and yields, and is currently pending examination in both Australia and the United States.

The guarantee provided by Dr Rajen is secondary, given in his personal capacity in favour of SCC, which is listed on The Stock Exchange of Hong Kong. The maximum amount recoverable under the guarantee is capped at approximately A\$1.6 million, being the amount of SCC’s capital contribution to the Joint Venture. The guarantee does not constitute an obligation of the Company.

Dr Rajen has provided the guarantee at SCC’s request to demonstrate the collective commitment of Holista and himself – as co-owner of the relevant patents – to the success of the joint venture, as SCC is providing all the needed funding. In providing this guarantee, Dr Rajen does not receive any material benefit from either Holista or SCC. The guarantee was a requirement of SCC to progress the transaction. By providing it, the Company secured the project-level joint venture capital required for the facility while avoiding a highly dilutive equity raising at the parent company level, thereby preserving existing shareholder value. Dr Rajen receives no direct or asymmetrical cash benefit for providing the guarantee, and his interests remain aligned with those of all Holista shareholders.

Dr Rajen holds 58,514,245 fully paid ordinary shares in the Company. SCC has not requested that any of those shares be provided as security for the guarantee, and

accordingly, no shares are secured in respect of the guarantee. To the extent any amount remains owing under the guarantee, the balance is intended to be satisfied following the realisation of the land and building referred to below. By way of correction to the Original Announcement, which stated that the guarantee is secured by the shares held in Holista, the Company confirms that the guarantee is not secured over Dr Rajen's shares in the Company. This remains a private guarantee to secure the needed funding for the success of this project.

Dr Rajen does not and will not have any formal or informal governance, advisory, operational, or decision-making role in the Joint Venture.

The obligations under the guarantee would be triggered only in the event that the Joint Venture ultimately does not succeed. For these purposes, the Joint Venture will be considered not to have succeeded only on the occurrence of one or more objective, quantifiable performance or regulatory triggers, being: a prolonged or material inability to secure commercial orders or to achieve the minimum commercial off-take targets required to sustain operations; a definitive failure to obtain the local council, state or federal building and development approvals required to construct or operate the facility; or an inability to secure the manufacturing, quality assurance or medical-grade certifications essential to produce and commercially distribute the products. In that event, all assets owned by the Joint Venture, including the land and building, would be realised and would not remain with the Company. To the extent any shortfall remains between the amount recovered on realisation and SCC's capital contribution, that shortfall would be satisfied by Dr Rajen under his secondary guarantee.

In relation to the Collie facility, the land is scheduled for purchase in June 2026, with construction expected to commence in August 2026, subject to obtaining the necessary regulatory approvals from the relevant local authorities.

Of the approximately A\$1.6 million contributed by SCC, approximately A\$1.1 million is allocated to building construction, with the remaining balance designated for working capital. Construction of the plant is expected to be completed within budget.

The Company and the Joint Venture do not expect any additional funding, beyond SCC's initial contribution, for the facility to achieve full operational status. The Company will provide further updates on the quantum, timing, and source of any such additional funding as the project progresses.

Other than as clarified above, the information in the Original Announcement remains current. This announcement has been authorised for release by the Board of Holista Colltech Limited.

**-- ENDS --**

### **About Holista Colltech Limited**

Holista Colltech Limited (ASX: HCT) is a Perth-based innovator in health and wellness solutions, listed on the Australian Securities Exchange. The Company operates across four core business divisions: Dietary Supplements, Healthy Food Ingredients, Ovine Collagen, and Infection Control Solutions.

Holista's portfolio includes market-leading nutritional supplements, patented low-GI food ingredients adopted by global food manufacturers, premium disease-free ovine

collagen, and all-natural, non-toxic sanitizers for consumer and industrial use. These offerings reflect Holista's commitment to combining the best of nature and science to support healthier modern lifestyles.

With a strong track record of research, development, and commercialization, Holista has pioneered several proprietary technologies in the global health and wellness sector. The Company remains dedicated to delivering sustainable, science-backed solutions that enrich lives and promote better living worldwide.